Nanotechnology: A Balm for the Challenges of Drug Delivery
This article was originally published in Start Up
Executive Summary
2007 was an awful year for drug delivery companies, and 2008 is shaping up to be no better. The share prices of many drug delivery companies are trading at or below their 10-year averages as investors realize that convenient delivery of large molecules that heretofore required painful injections isn't necessarily a compelling commercial opportunity. Still, intrepid venture capitalists are investing in some companies that are capitalizing on one key difference: these fledgling start-ups use nanotechnology to create therapies that are significantly different--especially in terms of safety and efficacy--from the first-generation drugs they hope to supplant.
You may also be interested in...
Another Twist in Myocet Plot With $55 Million Zoticon-Led Financing for Sopherion
Zoticon has licensed the liposomal formulation of doxorubicin (Myocet) from Sopherion Therapeutics, essentially rescuing the company on the edge of collapse and creating a new vehicle for Myocet's development.
Another Twist in Myocet Plot With $55 Million Zoticon-Led Financing for Sopherion
Zoticon has licensed the liposomal formulation of doxorubicin (Myocet) from Sopherion Therapeutics, essentially rescuing the company on the edge of collapse and creating a new vehicle for Myocet's development.
FDA Ramps Up Data Gathering On How To Regulate Nanotech In Drugs, Biologics
By 2015, some predict, nanotechnology will play a critical role in up to 60% of biopharma products.